A randomized, double-blind, multi-center comparison of the efficacy and safety of certoparin [certoparin sodium] (3000 U anti-xa o.d.) with unfractionated heparin (5000 IU t.i.d.) in the prophylaxis of thromboembolic events in acutely ill medical patients.

Trial Profile

A randomized, double-blind, multi-center comparison of the efficacy and safety of certoparin [certoparin sodium] (3000 U anti-xa o.d.) with unfractionated heparin (5000 IU t.i.d.) in the prophylaxis of thromboembolic events in acutely ill medical patients.

Completed
Phase of Trial: Phase III

Latest Information Update: 24 Jul 2012

At a glance

  • Drugs Certoparin sodium; Heparin
  • Indications Deep vein thrombosis; Pulmonary embolism; Thromboembolism
  • Focus Therapeutic Use
  • Acronyms CERTIFY
  • Sponsors Novartis
  • Most Recent Events

    • 01 Nov 2011 Results published in Thrombosis Research.
    • 07 Apr 2010 Additional descriptors, pt segments added, and centres added.
    • 24 Mar 2010 Actual end date (Jun 2009) and actual number of patients (3244) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top